CYP genotyping in psychopharmacological treatment;CYP-genotyping ved psykofarmakologisk behandling

Tidsskrift for den Norske Laegeforening

Volumn 125, Issue 21, 2005, Pages 2953-2955

  Rudberg, Ida ^a   Solberg, Dag Kristen ^a   Refsum, Helge ^a  

^a Psykofarmakologisk Avdeling   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMISULPRIDE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIAZEPAM; DULOXETINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; UNINDEXED DRUG; ZIPRASIDONE; ZOLPIDEM; ZUCLOPENTHIXOL;

DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PHARMACOGENETICS; PSYCHOPHARMACOTHERAPY; SHORT SURVEY;

CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; MUTATION; PHARMACOGENETICS; PSYCHOTROPIC DRUGS; VARIATION (GENETICS);

EID: 27944477786     PISSN: 00292001     EISSN: 00292001     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (10)

1. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250: 186-200.
2. Poolsup N, Li Wan PA, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 2000; 25: 197-220.
3. Spigset O. Cytokrom P-450-systemet. Tidsskr Nor Lægeforen 2001; 121: 3296-8.
4. Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41: 453-70.
5. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25: 193-200.
6. Ma JD, Nafziger AN, Bertino JS jr. Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers. J Clin Pharmacol 2004; 44: 447-56.
7. Andersen S, Refsum H, Tanum L. Bruk av psykofarmaka - bør serumkonsentrasjonen kontrolleres? Tidsskr Nor Lægeforen 2004; 124: 2362-4.
8. Kirchheiner J, Brosen K, Dahl ML et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173-92.
9. Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 2001; 41: 535-67.
10. Eap CB, Sirot EJ, Baumann P. Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies. Ther Drug Monit 2004; 26: 152-5.